Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Lokavant provides clinical trial intelligence
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Subscribe To Our Newsletter & Stay Updated
